REUTERS: Moderna Inc and Merck & Co on Tuesday told a US Congressional panel that they expect to profit from their coronavirus vaccines once approved, amid concerns the vaccines may not be accessible to all.
Gerberding and a representative from Moderna did not comment on the price they have in mind for their vaccines at the hearing, which focused on efforts to develop a safe, effective and widely accessible vaccine against COVID-19, which has claimed 600,000 lives globally. "We didn't access federal funding solely for the reason that we wanted to move the vaccine faster to the clinic," Young said.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오: